GLP-1 drugs are linked to fewer heart attacks, strokes and deaths in diabetes

GLP-1 receptor agonists are a class of drugs used in diabetes, and the biggest question hanging over any diabetes drug is not what it does to blood sugar but what it does to hearts. Several large cardiovascular outcome trials of this class have now reported, each powered to detect safety rather than to settle every subgroup question. Pooling them answers what no single trial can: across the whole class, do these drugs reduce major adverse cardiovascular events, and does any benefit hold regardless of sex, advanced age and obesity?

The authors searched MEDLINE, EMBASE, the Cochrane database and clinicaltrials.gov up to 15 June 2019 for controlled trials of GLP-1 receptor agonists with a cardiovascular endpoint. Seven trials qualified, all comparing the drugs against placebo. The principal endpoint was major adverse cardiovascular events, with secondary endpoints including myocardial infarction, stroke, cardiovascular and all-cause mortality, and hospitalisation for heart failure. Odds ratios were calculated for each outcome, and subgroup analyses examined whether the effect on major events differed by gender, advanced age or obesity.

Treatment with GLP-1 receptor agonists was associated with reduced odds of major adverse cardiovascular events, with an odds ratio of 0.87. Cardiovascular mortality, all-cause mortality, myocardial infarction and stroke were each also reduced, with odds ratios of 0.88, 0.90, 0.91 and 0.86 respectively. Hospitalisation for heart failure moved in the same direction but was not statistically significant, at 0.93. The subgroup analyses showed the reduction in major events held irrespective of gender, advanced age and obesity, so no group examined appeared to miss out on the benefit.

This updated pooling strengthens the case that cardiovascular benefit is a property of the GLP-1 receptor agonist class rather than a quirk of a single trial, and that the effect is not moderated by gender or body mass index. The trials were conducted in high-risk patients with diabetes, so the findings describe that population specifically. The authors flag one open question explicitly: whether the drugs act differently in people who have already had a cardiovascular event compared with those who have not, which they say merits further investigation.

If you or someone close to you has diabetes and these drugs come up, this is a reason to see them as more than glucose medication: across seven placebo-controlled trials they were associated with fewer heart attacks, strokes and deaths. It says nothing about people without diabetes, and nothing here covers the weight-loss uses the class has since become famous for. Treatment decisions sit with a prescriber; what this adds is context on why the class carries real cardiovascular weight in those conversations.